Bifonazole (trade name Canespor among others[1]) is an imidazole antifungal drug used in form of ointments.
Clinical data | |
---|---|
Trade names | Canespor, many others |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Topical |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
ChEBI |
|
ChEMBL |
|
CompTox Dashboard (EPA) |
|
ECHA InfoCard | 100.056.651 |
Chemical and physical data | |
Formula | C22H18N2 |
Molar mass | 310.400 g·mol−1 |
3D model (JSmol) |
|
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
It was patented in 1974 and approved for medical use in 1983.[2] There are also combinations with carbamide for the treatment of onychomycosis.
The most common side effect is a burning sensation at the application site. Other reactions, such as itching, eczema or skin dryness, are rare.[3] Bifonazole is a potent aromatase inhibitor in vitro.[4][5]
Bifonazole has a dual mode of action. It inhibits fungal ergosterol biosynthesis at two points, via transformation of 24-methylendihydrolanosterol to desmethylsterol, together with inhibition of HMG-CoA. This enables fungicidal properties against dermatophytes and distinguishes bifonazole from other antifungal drugs.[3][6]
Six hours after application, bifonazole concentrations range from 1000 μg/cm3 in the stratum corneum to 5 μg/cm3 in the papillary dermis.[3]